Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-2-19
pubmed:abstractText
Both virus-associated haemophagocytic syndrome (HPS) and human immunodeficiency virus-associated multi-centric Castleman's disease (HIV-MCD) induced by human herpesvirus-8 (HHV-8) are extremely rare. We therefore wished to investigate their occurrence together, and establish the degree of cytokine activation present. From a prospective cohort of individuals with HIV-MCD, we investigated the incidence and outcomes of HPS and measured 15 inflammatory cytokines and the plasma HHV-8 viral loads before and during follow-up. Of 44 patients with HIV-MCD with an incidence of 4.3/10,000 patient years, four individuals (9%) were diagnosed with HPS. All are in remission (range 6-28 months) following splenectomy, etoposide and rituximab-based therapy. Plasma HHV-8 levels were raised markedly at presentation (median 3,840,000 copies/ml). Histological samples from spleen, splenic hilar lymph nodes and bone marrow demonstrated increased phagocytosis by histiocytes and presence of HHV-8-infected plasmablasts outside the follicles. Surprisingly, many known inflammatory plasma cytokines were not elevated, although interleukin (IL)-8 and interferon-gamma were increased in all cases and IL-6 levels were raised in three of four patients. HPS in the setting of HIV-MCD is common and treatment can be successful provided the diagnosis is made appropriately. Systemic activation of cytokines was limited, suggesting that immunosuppressive therapy with steroids is not indicated in HHV-8-driven HPS.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-10192453, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-10214873, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-10515891, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-10583959, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-10931148, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-10979949, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-11385615, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-12239144, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-12467968, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-12819472, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-12856221, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-15223659, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-15465418, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-16330952, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-16448985, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-16937360, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-17893313, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-17981475, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-18024800, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-18045564, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-18087054, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-18178978, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-18260115, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-1992521, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-225008, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-6886145, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-8391350, http://linkedlifedata.com/resource/pubmed/commentcorrection/19222502-9121398
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1365-2249
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
154
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
399-405
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19222502-Adult, pubmed-meshheading:19222502-Antibodies, Monoclonal, pubmed-meshheading:19222502-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:19222502-Antineoplastic Agents, Phytogenic, pubmed-meshheading:19222502-Antiretroviral Therapy, Highly Active, pubmed-meshheading:19222502-Combined Modality Therapy, pubmed-meshheading:19222502-Cytokines, pubmed-meshheading:19222502-Drug Therapy, Combination, pubmed-meshheading:19222502-Etoposide, pubmed-meshheading:19222502-Giant Lymph Node Hyperplasia, pubmed-meshheading:19222502-HIV Infections, pubmed-meshheading:19222502-Herpesvirus 8, Human, pubmed-meshheading:19222502-Humans, pubmed-meshheading:19222502-Immunologic Factors, pubmed-meshheading:19222502-Lymphohistiocytosis, Hemophagocytic, pubmed-meshheading:19222502-Male, pubmed-meshheading:19222502-Middle Aged, pubmed-meshheading:19222502-Splenectomy, pubmed-meshheading:19222502-Young Adult
pubmed:year
2008
pubmed:articleTitle
The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease.
pubmed:affiliation
Department of Oncology, Imperial College School of Medicine, Chelsea and Westminster Hospital, London UK. j.stebbing@imperial.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't